Skip to content
value.today

Camp4 Therapeutics Corp

Total raised
$180 M
3 rounds on record
Latest round
$100 M
Jun 2022
First round on record
Apr 2018
Today
Went public
See the company page

Camp4 Therapeutics Corp is listed today as CAMP4 Therapeutics Corporation: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Camp4 Therapeutics Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2022$100 MNo. 3$50 to $250 million

Camp4 Therapeutics Corp: Raise no. 3, Jun 2022

Investors in this round

16 investors had bought by the notice of Jun 21, 2022: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Camp4 Therapeutics Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$100 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alfica Sehgal · Executive Officer
  • Ann Barbier · Executive Officer
  • Caleb Moore · Executive Officer
  • David Bumcrot · Executive Officer
  • Josh Mandel-Brehm · Executive Officer, Director
  • Kelly Gold · Executive Officer
  • Michelle Gates · Executive Officer
  • Amir Nashat · Director
  • Andrew J. Schwab · Director
  • James J. Boylan · Director
  • Jorge Conde · Director
  • Michael Higgins · Director
  • Paula Ragan · Director
  • Ravi I. Thadhani · Director
  • Richard Young · Director
  • Shaan I. Gandhi · Director
  • Steve Holtzman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Josh Mandel-Brehm, President and ceo. Source: SEC Form D, newest notice filed Jun 21, 2022. Read the notice at the SEC.

equitySEC
Mar 2021$45 MNo. 2$10 to $50 million

Camp4 Therapeutics Corp: Raise no. 2, Mar 2021

Investors in this round

7 investors had bought by the notice of Oct 29, 2021: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Camp4 Therapeutics Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$45 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alfica Sehgal · Executive Officer
  • Caleb Moore · Executive Officer
  • David Bumcrot · Executive Officer
  • Josh Mandel-Brehm · Executive Officer, Director
  • Kelly Gold · Executive Officer
  • Michelle Gates · Executive Officer
  • Amir Nashat · Director
  • Andy Schwab · Director
  • Jorge Conde · Director
  • Michael Higgins · Director
  • Paula Ragan · Director
  • Ravi Thadhani · Director
  • Richard Young · Director
  • Shaan Gandhi · Director
  • Steve Holtzman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Josh Mandel-Brehm, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Oct 29, 2021. Read the notice at the SEC.

equitySEC
Apr 2018$34 MNo. 1$10 to $50 million

Camp4 Therapeutics Corp: Raise no. 1, Apr 2018

Investors in this round

6 investors had bought by the notice of Sep 25, 2018: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Camp4 Therapeutics Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$34 M of $34 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Josh Mandel-Brehm · Executive Officer, Director
  • Amir Nashat · Director
  • Jorge Conde · Director
  • Michael Higgins · Director
  • Richard Young · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Josh Mandel-Brehm, President and ceo. Source: SEC Form D, newest notice filed Sep 25, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company CAMP4 Therapeutics Corporation, its revenue in fiscal 2025 came from these business segments: R&D $3.50 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Camp4 Therapeutics Corp chose not to state its revenue in its newest notice of a funding round (Jun 2022).

    SEC Form D · Jun 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2022

Products and services#

No products or services of Camp4 Therapeutics Corp are on record.

Investors#

18 named in official filings. Open an investor to see everything it has backed.

Investors in Camp4 Therapeutics Corp
InvestorKindAmountRoundRoleSource
5AM Opportunities II (GP), LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
5AM Opportunities II, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
5AM Partners VI, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
5AM Ventures VI, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
AH Bio Fund I, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
AH Equity Partners Bio I, L.L.C.Private equitynot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Enavate Sciences GP, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Everest Aggregator, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Josh Mandel-BrehmPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2024)SEC Form 3
Northpond Ventures GP II, LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Northpond Ventures GP, LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Northpond Ventures II, LPVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Northpond Ventures, LPVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Polaris Entrepreneurs' Fund VII, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Polaris Management Co. VII, L.L.C.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Polaris Partners VII, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Richard A. YoungPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2024)SEC Form 3
Steven H. HoltzmanPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2024)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 16 investors.

Largest shareholders today

Institutions holding CAMP4 Therapeutics Corporation shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Camp4 Therapeutics Corp
NameRoleNamed in
Alfica SehgalExecutive officerJun 2022
Ann BarbierExecutive officerJun 2022
Caleb MooreExecutive officerJun 2022
David BumcrotExecutive officerJun 2022
Josh Mandel-BrehmExecutive officerJun 2022
Kelly GoldExecutive officerJun 2022
Michelle GatesExecutive officerJun 2022
Amir NashatDirectorJun 2022
Andrew J. SchwabDirectorJun 2022
James J. BoylanDirectorJun 2022
Jorge CondeDirectorJun 2022
Josh Mandel-BrehmDirectorJun 2022
Michael HigginsDirectorJun 2022
Paula RaganDirectorJun 2022
Ravi I. ThadhaniDirectorJun 2022
Richard YoungDirectorJun 2022
Shaan I. GandhiDirectorJun 2022
Steve HoltzmanDirectorJun 2022
Andy SchwabDirectorOct 2021
Ravi ThadhaniDirectorOct 2021
Shaan GandhiDirectorOct 2021

Went public since 2024. Its SEC number is that of a company listed on a stock exchange.